Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.

NCT00397345 is registered in ClinicalTrials.gov with Oxford BioMedica as lead sponsor.

NCT NCT00397345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00397345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.
Lead sponsor
Oxford BioMedica
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
December 31, 2009
Enrollment
733 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal carcinoma